We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
2012 - Review: Omega-3 fatty acid supplements provide no protective benefit in cardiovascular disease.
- Authors
Halim, Sharif A.; Newby, L. Kristin
- Abstract
Question: In patients with cardiovascular (CV) disease, are omega-3 fatty acid supplements (eicosapentaenoic acid [EPA] and docosahexaenoic acids [DHA]) effective for secondary prevention? Review scope: Included studies compared omega-3 fatty acid supplements used for <img alt=">=" src="ge9.gif"/> 1 year with placebo in adults <img alt=">=" src="ge9.gif"/> 18 years of age who had a history of CV disease, and reported such outcome measures as CV events, sudden cardiac death, CV death, all-cause mortality, myocardial infarction, congestive heart failure, and transient ischemic attack (TIA) or stroke. Review methods: PubMed, EMBASE/Excerpta Medica, and Cochrane Library (all to Apr 2011), and bibliographies were searched for English-language, double-blind, placebo-controlled, randomized trials. 14 trials (n = 20 485, mean age 63 y, 79% men) met the selection criteria. Mean follow-up was 2 years, and mean daily dose of EPA or DHA was 1.7 g/d. 6 trials had Jadad scores of 5 out of 5, 7 had scores of 4, and 1 had a score of 3. Main results: Meta-analysis showed that omega-3 fatty acids reduced CV mortality compared with placebo (Table). Groups did not differ for CV events, sudden cardiac mortality, all-cause mortality, myocardial infarction, congestive heart failure, or TIA or stroke (Table). Conclusion: In patients with cardiovascular disease, omega-3 fatty acid supplements do not reduce adverse cardiovascular outcomes.
- Publication
ACP Journal Club, 2012, Vol 157, Issue 4, p1
- ISSN
1056-8751
- Publication type
Academic Journal
- DOI
10.7326/0003-4819-157-4-201208210-02003